glp 1 agonists for diabetes Glucagon-like peptide-1 (GLP-1) receptor are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 mellitus and #obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic Researchers find GLP-1 medications safe

And if our body already produces GLP-1, why do we need more from outside

Neuropsychopharmacology 43, 20002008

Key Pharmacokinetic Parameters The table below describes the key pharmacokinetic parameters for DPP-4 inhibitors: Cautions and contraindications Cautions and contraindications for the use of DPP-4 inhibitors are listed below: Adverse effects Other adverse effects include: Increased risk of infection with saxagliptin, alogliptin and vildagliptin Hypersensitivity reactions (including anaphylaxis, angioedema, stevens-johnson syndrome) Sitagliptin: interstitial lung disease, impaired renal function, thrombocytopenia, and acute renal failure

Hence, these investigations illustrate that GLP-1R agonism effectively slows down the advancement of atherosclerosis through a glycemia-independent and endothelial GLP-1R-dependent pathway

4,9 References Celletti, F., Farrar, J., & De Regil, L

Understanding Ozempic: What It Is and How It Works Ozempic is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the effects of the GLP-1 hormone in the body